1. Introduction

Biohybrid Robotics Regulation in Russia concerns the legal framework governing the development, manufacture, testing, commercialisation and use of robotic systems that combine biological materials with artificial mechanical, electronic or computational components.

Biohybrid robotics combines biological and engineering technologies to produce systems that may contain:

Living muscle cells used to generate mechanical movement.

Biological neurons integrated with electronic circuits.

Engineered tissues connected to robotic structures.

Living microorganisms used in robotic sensing systems.

Artificial intelligence controlling biological components.

Bioengineered organs or tissues integrated with mechanical devices.

For example, a robotic hand powered by laboratory-grown muscle tissue or a robot controlled by cultured neural cells could raise questions involving medical law, biotechnology regulation, product safety, human rights and civil liability.

Legal position in Russia

Russia does not have a single comprehensive federal statute specifically governing biohybrid robotics. Instead, its regulation must be understood through several existing legal frameworks, including:

Civil Code of the Russian Federation.

Federal Law No. 323-FZ on the Fundamentals of Healthcare Protection.

Federal Law No. 180-FZ on Biomedical Cell Products.

Federal Law No. 86-FZ on State Regulation in the Field of Genetic Engineering.

Federal Law No. 492-FZ on Biological Safety.

Federal Law No. 152-FZ on Personal Data.

Technical regulation and medical-device registration requirements.

The legal challenge is determining which rules apply when a single system combines living biological material, mechanical equipment and artificial intelligence.

2. Main Legislative Framework

A. Civil Code of the Russian Federation

The Russian Civil Code provides the foundation for determining responsibility when biohybrid robotic systems cause injury or property damage.

Important provisions include:

Article 1064 – General liability

If a biohybrid robot injures a person because of negligent design, improper programming or unsafe operation, the responsible person may be required to compensate the victim.

For example:

A Russian biotechnology company develops a robotic arm containing living muscle cells. A software malfunction causes the arm to move uncontrollably and injure a laboratory technician.

Potentially responsible parties include:

The manufacturer.

The software developer.

The laboratory operator.

The maintenance contractor.

Responsibility depends on the evidence, the applicable legal duty and the causal connection between the conduct and the injury.

Article 1079 – Increased-danger liability

This provision is particularly important where a biohybrid robotic system constitutes a source of increased danger.

The owner or lawful possessor of such a source may be liable for resulting harm even without proof of fault, subject to the statutory defences.

However, not every laboratory robot automatically qualifies as a source of increased danger. The court must assess the nature of the equipment and its operation.

Article 1095 – Defective product liability

A manufacturer or seller may be required to compensate harm caused by defective design, manufacturing defects or insufficient product information, independently of fault in cases covered by this provision.

This could apply to defective robotic actuators, contaminated biological components or inadequately disclosed safety risks.

rospatent.gov.ru+2

B. Federal Law No. 323-FZ of 2011 – Healthcare Protection

The Federal Law on the Fundamentals of Healthcare Protection regulates medical activities and the use of medical technologies.

Its importance increases when biohybrid robotics is used for:

Robotic surgery.

Rehabilitation.

Artificial limbs.

Neural stimulation.

Biological tissue replacement.

Implantable robotic systems.

Medical monitoring.

Article 38 – Medical devices

Medical devices must satisfy the applicable registration requirements before being placed into circulation in Russia, subject to statutory exceptions.

Roszdravnadzor supervises medical-device registration and safety.

A biohybrid medical robot may require medical-device registration depending on its intended purpose, functionality and legal classification.

A critical issue is that a product combining biological and mechanical components may not fit neatly into a conventional medical-device category.

edu.rosminzdrav.ru+2

C. Federal Law No. 180-FZ of 2016 – Biomedical Cell Products

This is one of the most relevant laws for biohybrid robotics.

It regulates biomedical cellular products intended for medical purposes, including their:

Development.

Preclinical research.

Clinical trials.

Examination.

State registration.

Production.

Quality control.

Storage and transportation.

Medical application.

For example, suppose a Russian research organisation creates a robotic leg powered by cultured human muscle cells.

If the biological component qualifies as a biomedical cellular product under this legislation, the relevant requirements of Law No. 180-FZ may apply.

The law also regulates the donation of biological material for the production of biomedical cellular products.

Importantly, Article 1 contains exclusions, including certain medical-device activities and the use of human cells and tissues for scientific and educational purposes. Therefore, not every biohybrid prototype automatically falls within this statute.

Roszdravnadzor supervises licensing of biomedical cellular product manufacturing, while state registration is handled through the applicable health-authority framework.

CIS Legislation+3

D. Federal Law No. 86-FZ of 1996 – Genetic Engineering Regulation

This legislation regulates genetic engineering activities involving genetically modified organisms and related environmental and health-protection issues.

It becomes relevant where biohybrid robotics incorporates:

Genetically modified microorganisms.

Engineered biological cells.

Genetically modified animal tissues.

Recombinant biological components.

Genetically modified organisms used in robotic sensing.

For example, a biohybrid sensor using genetically modified bacteria to detect toxic substances may raise questions under this legislation.

Important limitation: Article 1 excludes the regulation of the procedures for applying genetic-engineering methods to humans and to tissues and cells within the human body. Consequently, the law should not be treated as a complete regulatory framework for human-integrated biohybrid technology.

A further development is Federal Law No. 43-FZ of 20 February 2026, which amended Law No. 86-FZ, with the relevant changes taking effect on 1 September 2026. These changes include provisions concerning human genetic data and its transfer.

CIS Legislation+2

E. Federal Law No. 492-FZ of 2020 – Biological Safety

The Biological Safety Law establishes a framework for protecting the population and environment against dangerous biological factors.

It is relevant to biohybrid robotics involving:

Pathogenic microorganisms.

Biologically hazardous materials.

Contaminated cellular cultures.

Laboratory biological waste.

Biological exposure risks.

Potential environmental release of dangerous biological agents.

For example, if a biohybrid robotic platform containing a hazardous biological agent leaks its biological material into the environment, biological safety and environmental protection requirements may become relevant.

The statute is not a general approval law for every biological robotic device. Its application depends on the biological risks involved.

CIS Legislation+1

3. Regulatory Authorities in Russia

Different government institutions may exercise authority over different aspects of biohybrid robotics.

A single biohybrid project may therefore require several regulatory assessments rather than one general robotics licence.

4. Registration and Approval of Biohybrid Robots

The regulatory classification of a biohybrid robot depends on its intended use and biological characteristics.

Typical regulatory pathway

Research and development

Identify the biological materials, mechanical components and intended application.

Biological safety assessment

Evaluate contamination, cell viability, biological exposure and environmental risks.

Preclinical testing

Conduct applicable laboratory and preclinical safety and performance studies.

Clinical and ethical assessment

Obtain applicable permissions and ethical approvals before human clinical research.

Regulatory registration

Determine whether medical-device registration, biomedical cellular product registration or both regulatory pathways are applicable.

Manufacturing and market supervision

Maintain quality controls, safety monitoring, traceability and incident reporting.

This is an analytical pathway, not a statutory six-step procedure applicable to every prototype.

5. Legal Issues Concerning Artificial Intelligence and Biological Components

Biohybrid robotics creates a distinctive problem because its biological and mechanical elements may respond differently to external conditions.

For example, an AI-controlled biohybrid robot might use cultured neurons to interpret signals and artificial actuators to produce movement.

Potential legal conflicts include:

1. Algorithmic malfunction: Whether the developer, manufacturer or operator is responsible when an AI decision causes injury.

2. Biological malfunction: Whether cellular deterioration, unexpected tissue growth or biological contamination constitutes a manufacturing or operational defect.

3. Human supervision: Whether the operator maintained adequate control over the system.

4. Safety transparency: Whether manufacturers adequately disclosed the risks of biological and software interactions.

5. Evidence preservation: Whether technical logs, biological samples and software records are sufficiently preserved to establish causation.

Russian legislation does not generally recognise an AI system or robot as an independent legal person. Consequently, responsibility must ordinarily be determined by examining the relevant natural persons and legal entities.

6. Important Case Laws and Judicial Decisions

Relevant judicial authorities

There is an important distinction: Russian courts have considered robotic medical equipment, autonomous technology and medical-device disputes, but the following decisions should not be presented as direct precedents involving living-tissue biohybrid robots. They are analogous authorities useful for analysing future disputes.

Case 1. UROGIN+ LLC v Moscow Regional FAS – 2026

Ninth Arbitration Court of Appeal, 7 May 2026, Case No. A40-340576/2025, Resolution No. 09АП-15734/26.

Facts:

UROGIN+ challenged a procurement decision involving a robotic surgical system manufactured by a Chinese company.

The dispute concerned technical specifications requiring the robotic surgical system to have a remote-operation capability.

The claimant argued that the requirement could restrict competition and questioned its compatibility with healthcare legislation.

Judicial findings:

The appellate court upheld the relevant procurement position, accepting the customer's justification for specifying the remote-surgery functionality.

The court considered the medical centre's requirements and the evidence supporting the uniqueness of the equipment.

Legal significance for biohybrid robotics:

Specialised robotic medical equipment may require specific safety and functional characteristics.

Procurement requirements must be assessed against their technical justification.

Remote operation introduces additional questions concerning control and operational safety.

Regulatory approval and procurement compliance are distinct legal questions.

Application: A Russian hospital purchasing a biohybrid surgical robot could face similar disputes concerning its biological functionality, remote operation and technical specifications.

ГАРАНТ

Case 2. Koplyov v LLC Da Vinci – 2026

Third Cassation Court of General Jurisdiction, 29 June 2026, Case No. 88-11356/2026.

Facts:

A patient challenged the cancellation of a scheduled dental appointment because medical equipment had malfunctioned.

The patient sought compensation for moral harm and other consumer-related remedies.

Judicial findings:

The lower courts rejected the patient's claims. The evidence showed that the equipment had been repaired and the medical provider had subsequently offered an opportunity to receive treatment.

The patient also confirmed that the eventual medical service had not caused injury.

Legal significance:

The decision illustrates the importance of establishing:

Whether equipment malfunction actually violated patient rights.

Whether the healthcare provider took reasonable corrective measures.

Whether legally compensable harm occurred.

Whether the provider fulfilled its contractual obligations.

Application: If a biohybrid robotic device becomes temporarily unusable because its biological component deteriorates, the healthcare provider's response and the consequences for the patient may become important in determining liability.

Caution: LLC Da Vinci in this dispute was the dental service provider; this was not a judgment about the Da Vinci robotic surgical platform.

3kas.sudrf.ru

Case 3. Russian Robotic Surgery Criminal Liability Research – 2023

Evgeniya Chernyh, Robots in Surgery: Who Should Be Held Criminally Responsible, Legal Science and Practice: Journal of Nizhny Novgorod Academy of the Ministry of Internal Affairs of Russia, 2023, Issue 3, pp. 80–84.

This is a scholarly legal analysis, not a court judgment.

Central issue:

Who should bear criminal responsibility when a robotic surgeon causes injury or death during an operation?

The research examines the difficulty of identifying the responsible human actor when a robotic system performs important surgical functions.

Legal significance:

The analysis is relevant to biohybrid robotics because a biological component may independently influence the movement or behaviour of a robotic system.

For example, if cultured neural cells generate unexpected control signals, investigators may need to establish whether the cause was:

Negligent system design.

Defective software.

Inadequate biological testing.

Improper operation.

Failure of human supervision.

Russian criminal responsibility ordinarily attaches to natural persons rather than companies or robots. Depending on the facts, provisions concerning negligent homicide, negligent injury or unsafe services may become relevant.

naukaru06.ru

Case 4. Mracek v. Intuitive Surgical, Inc. – 2010 (Comparative Authority)

United States Court of Appeals for the Third Circuit, Case No. 09-2042, 28 January 2010.

Facts:

The claimant underwent prostate surgery using a Da Vinci surgical robot. The equipment displayed error messages and became unusable during the operation.

The surgical team subsequently completed the procedure using conventional laparoscopic instruments.

The claimant brought claims involving negligence, product liability and alleged malfunction.

Legal significance for Russian law:

Although this is an American case, it provides a useful comparative example of how robotic medical equipment can create disputes concerning:

Product defects.

Manufacturer responsibility.

Technical malfunction.

Medical negligence.

Evidence of causation.

The case can inform comparative legal analysis, but it does not establish Russian legal precedent.

GovInfo

7. Criminal Liability for Biohybrid Robotic Accidents

The Russian Criminal Code may become relevant where a biohybrid robot causes serious injury, death or a violation of legally protected safety requirements.

For example, assume a laboratory manager knowingly allows a biohybrid robotic device to operate despite serious safety defects.

If an accident results in a person's death, Article 109 or another applicable provision could be examined depending on the facts and the responsible person's conduct.

Criminal responsibility must be established individually. A technical malfunction alone does not automatically establish a crime.

8. Constitutional and Human Rights Issues

Biohybrid robotics may raise constitutional questions when biological technology is integrated with the human body.

Important provisions of the Russian Constitution include:

Article 20: Right to life.

Article 21: Protection of human dignity.

Article 23: Privacy and personal and family secrets.

Article 24: Restrictions on collecting, storing, using and disseminating information about private life.

Article 41: Right to healthcare and medical assistance.

Important legal controversies

A. Biological autonomy

Can a person freely refuse the implantation or use of a biohybrid device?

B. Neural privacy

Who controls neural signals collected by a biohybrid robotic system?

C. Informed consent

Must patients receive separate explanations about biological, mechanical and AI-related risks?

D. Human dignity

Could experimental integration of biological tissues and robotic structures violate human dignity or bodily integrity?

E. Genetic information

Who may collect, retain or transfer genetic information generated through biological components?

The Federal Law No. 152-FZ on Personal Data is also relevant where biohybrid devices process identifiable personal or biometric information.

9. Intellectual Property and Ownership Disputes

Biohybrid robotics may generate disputes involving patents, biological materials and software ownership.

The Russian Civil Code's intellectual-property provisions, particularly Part IV, are relevant.

Potential disputes include:

Ownership of robotic hardware inventions.

Patenting of technical methods for integrating living tissues with mechanical structures.

Copyright protection for control software.

Ownership and licensing of biological manufacturing technologies.

Trade-secret protection for cell-cultivation techniques.

Disputes over employee-created inventions.

A critical distinction must be maintained between patentable technical inventions and biological material itself.

A patent claim concerning a new technical method of connecting cultured muscle tissue to a robotic actuator should be assessed differently from a claim attempting to monopolise naturally occurring biological material.

10. Environmental and Biosecurity Liability

Biohybrid robots can create environmental risks if their biological components escape containment or are improperly discarded.

Potential problems include:

Accidental release of genetically modified organisms.

Contamination of laboratory environments.

Improper disposal of biological waste.

Spread of biological agents.

Uncontrolled survival of biological components.

Damage to ecosystems.

Depending on the circumstances, Federal Laws No. 492-FZ and No. 86-FZ, environmental legislation and applicable sanitary requirements may become relevant.

Manufacturers and research organisations should establish biological containment, waste-management, emergency-response and traceability procedures.

11. Major Legal Challenges in Russia

12. Recommendations for Future Russian Legislation

Russia could develop a dedicated regulatory framework covering the following areas.

1. Biohybrid Robotics Registration Act

Establish a classification system for industrial, medical, experimental and research-oriented biohybrid robots.

2. Biological Component Safety Standards

Introduce specific standards for cellular viability, biological containment, tissue stability and contamination prevention.

3. Mandatory Risk Assessment

Require manufacturers to evaluate biological, mechanical, electronic and AI-related risks together.

4. Human Consent Protection

Establish clear rules for consent, withdrawal of consent and the use of donated human biological materials.

5. Liability Allocation

Clarify the responsibilities of manufacturers, software developers, laboratories, hospitals and operators.

6. Biohybrid Accident Reporting

Create a system for reporting serious injuries, biological failures, unexpected behaviour and environmental incidents.

7. Cross-Border Regulatory Cooperation

Develop procedures for international research collaboration, biological-material transportation and recognition of relevant safety assessments.

13. Conclusion

Biohybrid Robotics Regulation in Russia is an emerging legal field situated at the intersection of biotechnology, robotics, artificial intelligence, medical law, civil liability and biological safety.

The existing Russian legislative framework provides several mechanisms for regulating biohybrid technologies, particularly through Federal Laws No. 323-FZ, No. 180-FZ, No. 86-FZ and No. 492-FZ.

The Civil Code provides important mechanisms for compensation when robotic or biological systems cause harm.

The judicial decisions concerning robotic surgical equipment and medical-device failures provide useful analogies for future litigation. However, they do not establish a comprehensive body of case law specifically addressing biohybrid robots.

Overall legal finding

The central legal problem is the absence of a unified regulatory classification and liability framework for robotic systems that combine living biological components with artificial mechanical and computational technologies.

Russia's future regulatory development will need to address biological safety, human dignity, medical consent, product responsibility, AI accountability and environmental protection together.

14. Important Legal Sources and Further Reading

Federal Law No. 180-FZ – Biomedical Cell Products.

Federal Law No. 492-FZ – Biological Safety.

Federal Law No. 86-FZ – Genetic Engineering Activities.

Federal Law No. 323-FZ – Healthcare Protection.

Civil Code of the Russian Federation.

Robots in Surgery: Who Should Be Held Criminally Responsible (2023).

UROGIN+ robotic surgery procurement dispute (2026).

Academic note: This is a legal research overview, not a substitute for checking the authoritative Russian-language legislation, its applicable amendments and the complete text of individual court decisions before relying on them in litigation or publication.